Mild Cognitive Impairment in Older People
Lancet 360:1963-1965, Burns,A., &Zaudig,M., 2002
CSF Detection of the 14-3-3 Protein in Unselected Patients with Dementia
Neurol 56:1528-1533, Burkhard,P.R.,et al, 2001
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Drugs for Alzheimer's Disease
BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
High-Dose Estradiol Improves Cognition for Women with AD, Results of a Randomized Study
Neurol 57:605-612, Asthana,S.,et al, 2001
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Positron Emission Tomography in Evaluation of Dementia
JAMA 286:2120-2127,2194, Silverman,D.H.S.,et al, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Current Concepts in Mild Cognitive Impairment
Arch Neurol 58:1985-1992, Petersen,R.C.,et al, 2001
Influence of Leisure Activity on the Incidence of Alzheimer's Disease
Neurol 57:2236-2242, Scarmeas,N.,et al, 2001
The Effect of Brain Atrophy on Cerebral Hypometabolism in the Visual Variant of Alzheimer Disease
Arch Neurol 58:480-486, Bokde,A.L.W.,et al, 2001
Pathological Correlates of Late-Onset Dementia in a Multicentre, Community-based Population in England and Wales
Lancet 357:169-175, Neuroapthology Group of the Medical Research Counc, 2001
Effect of Donepezil on Brain Acetylcholineserase Activity in Patients with AD Measured by PET
Neurol 56:408-410, Shinotoh,H.,et al, 2001
Use of Specialized Coagulation Testing in the Evaluation of Patients with Acute Ischemic Stroke
Neurol 56:624-627, Bushnell,C.,et al, 2001
Magnetic Resonance Spectroscopy in AD
Neurol 56:592-598, Valenzuela,M.J.,et al, 2001
Age-Related Memory Decline
Arch Neurol 58:360-364, Small,S.A., 2001
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Hormone Replacement Therapy and Cognition
JAMA 285:1489-1499, LeBlanc,E.S.,et al, 2001
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
A Reevaluation of the Duration of Survival After the Onset of Dementia
NEJM 344:1111-1116, Wolfson,C.,et al, 2001
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Might Olfactory Dysfunction be a Marker of Early Alzheimer's Disease?
Lancet 355:84-85, Burns,A., 2000
Estrogen for Alzheimer's Disease in Women, Randomized, Double-Blind, Placebo-Controlled Trial
Neurol 54:295-301, Henderson,V.W.,et al, 2000
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease
ArchNeurol 57:339-344, Fox,N.C.,et al, 2000
Diagnostic Accuracy of Dementia with Lewy Bodies
ArchNeurol 57:347-351, Hohl,U.,et al, 2000
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease
JAMA 283:1007-1015,1055, Mulnar,R.A.,et al, 2000
Progression of Parkinsonian Signs in Alzheimer's Disease
Neurol 54:1284-1289, Wilson,R.S.,et al, 2000
Practice Parameter: Risk of Driving and Alzheimer's Disease (An Evidence-Based Review)
Neurol 54:2205-2211, Dubinsky,R.M.,et al, 2000
The Preclinical Phase of Alzheimer Disease
Arch Neurol 57:808-813, Elias,M.F.,et al, 2000
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Smoking and Dementia in Male British Doctors: Prospective Study
BMJ 320:1097-1102,1087, Doll,R.,et al, 2000
Variability of the Mini-Mental State Examination in Dementia
Neurol 54:1538-1539, Doraiswamy,P.M.&Kaiser,L., 2000
Survival in End-Stage Dementia Following Acute Illness
JAMA 284: 47-52, 87, Morrison,R.S. & Siu,A.L., 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Immunization for Alzheimer's Disease: A Shot in the Arm or a Whiff?
Ann Neurol 48:553-555, Levey,A.I., 2000
Anti-Inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Arch Neurol 57:1586-1591, Broe,G.A.,et al, 2000
Treatment of Agitation in AD
Neurol 55:1271-1278,1247, Teri,L.,et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
The Value of Informant Versus Individual's Complaints of Memory Impairment in Early Dementia
Neurol 55:1724-1726, Carr,D.B.,et al, 2000
Screening for Dementia with the Memory Impairment Screen
Neurol 52:231-238,224, Buschke,H.,et al, 1999
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Mild Cognitive Impairment, Clinical Characterization and Outcome
Arch Neurol 56:303-308, Petersen,R.C.,et al, 1999
Diagnosis, Management, and Treatment of Alzheimer Disease, A Guide for the Internist
Arch Int Med 159:789-798, Richards,S.S.&Hendrie,H.C., 1999